Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging

• Status: Completed
• Trial end date: 2018-03-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to measure the changes in cardiac function during a Lexiscan pharmacologic stress test using cardiac magnetic resonance imaging test.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Timothy M. Bateman
• Collaborators: Saint Luke's Cardiovascular Consultants; Saint Luke's Health System
• Treatments: Regadenoson

Criteria

Inclusion Criteria:

• Myocardial rest/regadenoson stress perfusion PET study within 60 days

• Normal rest LVEF (greater than or equal to 50%)

• No change in symptoms or treatment between the PET and the MRI study

• Willing to consent to the study

• Male or female who is either post-menopausal, surgically sterile, or if has a childbearing potential, a negative pregnancy test within 2 days prior to the MRI study.

Exclusion Criteria:

• Renal dysfunction (estimated glomerular filtration rate < 60 mL/min/1.73m2) within 6 months

• Metallic implants, pacemaker, blood vessel clip (contra-indicated for MRI)

• Patient size exceeds MRI bore/table limits: (Max body diameter > 60 cm, weight > 136 kg)

• History of gadolinium contrast allergy or intolerance

• Second or third degree AV block

• Sinus node dysfunction

• Acute myocardial infarction (past 3 months)

• Actively wheezing or with acute asthma or bronchospastic attacks requiring changes in therapy within the past 30 days

• Patients that have experienced a previous hypersensitivity reaction thought to be related to regadenoson